| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Preventive Health Services | 12 | 2023 | 159 | 4.510 |
Why?
|
| Mass Screening | 15 | 2023 | 661 | 4.000 |
Why?
|
| Advisory Committees | 15 | 2024 | 110 | 3.170 |
Why?
|
| Early Detection of Cancer | 8 | 2023 | 501 | 2.620 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 598 | 2.400 |
Why?
|
| Counseling | 8 | 2020 | 189 | 2.390 |
Why?
|
| Practice Guidelines as Topic | 11 | 2021 | 318 | 1.830 |
Why?
|
| Humans | 65 | 2024 | 17611 | 1.780 |
Why?
|
| Ankle Brachial Index | 3 | 2018 | 8 | 1.690 |
Why?
|
| Health Behavior | 6 | 2020 | 359 | 1.680 |
Why?
|
| Evidence-Based Medicine | 11 | 2023 | 185 | 1.640 |
Why?
|
| Exercise | 4 | 2020 | 489 | 1.530 |
Why?
|
| Syphilis | 2 | 2022 | 17 | 1.450 |
Why?
|
| Colorectal Neoplasms | 6 | 2021 | 613 | 1.430 |
Why?
|
| Health Equity | 3 | 2024 | 20 | 1.300 |
Why?
|
| United States | 22 | 2023 | 3956 | 1.200 |
Why?
|
| Research Design | 5 | 2020 | 374 | 1.170 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 57 | 1.160 |
Why?
|
| Occult Blood | 4 | 2021 | 153 | 1.110 |
Why?
|
| Peripheral Arterial Disease | 2 | 2018 | 13 | 1.070 |
Why?
|
| Adult | 25 | 2024 | 7598 | 1.060 |
Why?
|
| Risk Assessment | 8 | 2022 | 1097 | 1.020 |
Why?
|
| Dementia | 2 | 2020 | 106 | 0.990 |
Why?
|
| Colonoscopy | 4 | 2022 | 251 | 0.970 |
Why?
|
| Behavior Therapy | 5 | 2015 | 146 | 0.960 |
Why?
|
| Primary Health Care | 5 | 2017 | 766 | 0.950 |
Why?
|
| Physicians | 5 | 2024 | 137 | 0.950 |
Why?
|
| Melanoma | 2 | 2023 | 35 | 0.940 |
Why?
|
| Minerals | 2 | 2022 | 9 | 0.930 |
Why?
|
| Vitamins | 2 | 2022 | 64 | 0.890 |
Why?
|
| Geriatrics | 2 | 2013 | 5 | 0.860 |
Why?
|
| Quality of Life | 5 | 2022 | 507 | 0.860 |
Why?
|
| Public Health | 1 | 2023 | 80 | 0.820 |
Why?
|
| Health Policy | 1 | 2023 | 122 | 0.800 |
Why?
|
| Quality Control | 1 | 2021 | 45 | 0.790 |
Why?
|
| Racism | 1 | 2021 | 19 | 0.770 |
Why?
|
| Review Literature as Topic | 3 | 2017 | 12 | 0.770 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 37 | 0.760 |
Why?
|
| Exercise Therapy | 3 | 2018 | 71 | 0.740 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.710 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 40 | 0.700 |
Why?
|
| Health Status Disparities | 1 | 2021 | 146 | 0.700 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 304 | 0.700 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 201 | 0.670 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 47 | 0.660 |
Why?
|
| Neoplasms | 2 | 2022 | 438 | 0.660 |
Why?
|
| Syphilis, Congenital | 1 | 2018 | 1 | 0.640 |
Why?
|
| Genetic Testing | 4 | 2013 | 70 | 0.630 |
Why?
|
| Penicillins | 1 | 2018 | 6 | 0.630 |
Why?
|
| Vascular Calcification | 1 | 2018 | 9 | 0.620 |
Why?
|
| Depressive Disorder, Major | 3 | 2024 | 124 | 0.620 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 58 | 0.610 |
Why?
|
| Braces | 1 | 2018 | 2 | 0.610 |
Why?
|
| Scoliosis | 1 | 2018 | 3 | 0.610 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 67 | 0.600 |
Why?
|
| Clinical Protocols | 1 | 2018 | 43 | 0.600 |
Why?
|
| Preventive Medicine | 1 | 2018 | 24 | 0.590 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 172 | 0.590 |
Why?
|
| Healthy Diet | 1 | 2017 | 4 | 0.580 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 11 | 0.580 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 134 | 0.570 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2018 | 136 | 0.550 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 140 | 0.550 |
Why?
|
| Asymptomatic Diseases | 4 | 2018 | 29 | 0.550 |
Why?
|
| Risk Factors | 8 | 2019 | 3325 | 0.520 |
Why?
|
| Female | 17 | 2023 | 12608 | 0.500 |
Why?
|
| Adenoma | 1 | 2016 | 93 | 0.490 |
Why?
|
| Decision Making | 2 | 2013 | 183 | 0.470 |
Why?
|
| Early Diagnosis | 4 | 2020 | 38 | 0.460 |
Why?
|
| Bone Density Conservation Agents | 3 | 2024 | 54 | 0.440 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2014 | 54 | 0.430 |
Why?
|
| Osteoporosis | 2 | 2024 | 74 | 0.420 |
Why?
|
| Aged | 10 | 2021 | 6095 | 0.420 |
Why?
|
| Diet | 1 | 2014 | 365 | 0.410 |
Why?
|
| Diverticulitis, Colonic | 2 | 2022 | 8 | 0.400 |
Why?
|
| Adolescent | 5 | 2023 | 3651 | 0.390 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 949 | 0.390 |
Why?
|
| Ultrasonography | 3 | 2021 | 35 | 0.390 |
Why?
|
| Male | 13 | 2023 | 10008 | 0.370 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2010 | 24 | 0.370 |
Why?
|
| Sigmoidoscopy | 3 | 2021 | 65 | 0.370 |
Why?
|
| Vomeronasal Organ | 2 | 2020 | 2 | 0.350 |
Why?
|
| Risk | 3 | 2021 | 516 | 0.340 |
Why?
|
| Dietary Supplements | 3 | 2022 | 87 | 0.330 |
Why?
|
| Sex Counseling | 1 | 2008 | 2 | 0.320 |
Why?
|
| Unsafe Sex | 1 | 2008 | 19 | 0.320 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 1900 | 0.290 |
Why?
|
| Policy | 2 | 2024 | 18 | 0.270 |
Why?
|
| Checklist | 2 | 2024 | 15 | 0.270 |
Why?
|
| Fibrinolytic Agents | 2 | 2018 | 44 | 0.260 |
Why?
|
| Caregivers | 2 | 2020 | 127 | 0.260 |
Why?
|
| Antidepressive Agents | 2 | 2024 | 155 | 0.260 |
Why?
|
| Aspirin | 2 | 2018 | 63 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 322 | 0.250 |
Why?
|
| Incidental Findings | 2 | 2016 | 26 | 0.240 |
Why?
|
| Rotavirus Infections | 2 | 2015 | 31 | 0.240 |
Why?
|
| Rotavirus Vaccines | 2 | 2015 | 50 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 5 | 0.230 |
Why?
|
| Primary Prevention | 2 | 2022 | 73 | 0.220 |
Why?
|
| Osteoporotic Fractures | 1 | 2024 | 39 | 0.220 |
Why?
|
| Olfactory Bulb | 2 | 2020 | 2 | 0.220 |
Why?
|
| Physical Examination | 1 | 2023 | 20 | 0.220 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2003 | 2 | 0.220 |
Why?
|
| Fructose | 1 | 2003 | 5 | 0.220 |
Why?
|
| Anticonvulsants | 1 | 2003 | 9 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 205 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2013 | 11 | 0.210 |
Why?
|
| Age Factors | 3 | 2021 | 917 | 0.210 |
Why?
|
| Conflict of Interest | 2 | 2019 | 5 | 0.210 |
Why?
|
| Disclosure | 2 | 2019 | 19 | 0.210 |
Why?
|
| Vitamin A | 1 | 2022 | 14 | 0.210 |
Why?
|
| beta Carotene | 1 | 2022 | 17 | 0.210 |
Why?
|
| Middle Aged | 6 | 2021 | 7911 | 0.200 |
Why?
|
| Thrombophilia | 1 | 2002 | 3 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2023 | 39 | 0.200 |
Why?
|
| Pregnancy | 2 | 2018 | 1494 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2002 | 5 | 0.200 |
Why?
|
| Genomics | 2 | 2012 | 55 | 0.200 |
Why?
|
| Fractures, Bone | 1 | 2023 | 91 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 268 | 0.190 |
Why?
|
| Communication | 1 | 2023 | 194 | 0.190 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 3 | 0.190 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 12 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 17 | 0.190 |
Why?
|
| Dyspnea | 1 | 2021 | 48 | 0.190 |
Why?
|
| Morphogenesis | 1 | 2020 | 1 | 0.180 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 1 | 0.180 |
Why?
|
| Smad4 Protein | 1 | 2020 | 1 | 0.180 |
Why?
|
| Axons | 1 | 2020 | 2 | 0.180 |
Why?
|
| Acute Disease | 4 | 2024 | 142 | 0.180 |
Why?
|
| Hypogonadism | 1 | 2020 | 4 | 0.170 |
Why?
|
| Dyslipidemias | 1 | 2020 | 62 | 0.170 |
Why?
|
| Independent Living | 1 | 2020 | 21 | 0.170 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2019 | 1 | 0.170 |
Why?
|
| Kallmann Syndrome | 1 | 2019 | 1 | 0.170 |
Why?
|
| Neuroglia | 1 | 2019 | 3 | 0.170 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 38 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 197 | 0.170 |
Why?
|
| Testosterone | 1 | 2020 | 22 | 0.170 |
Why?
|
| Neurogenesis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Models, Statistical | 1 | 2021 | 177 | 0.170 |
Why?
|
| Neurons | 1 | 2019 | 10 | 0.170 |
Why?
|
| Authorship | 1 | 2019 | 5 | 0.170 |
Why?
|
| Pancreas | 1 | 2019 | 14 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 415 | 0.160 |
Why?
|
| Incidence | 3 | 2018 | 1255 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 255 | 0.160 |
Why?
|
| Postoperative Complications | 1 | 2019 | 102 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 28 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 22 | 0.160 |
Why?
|
| Rotavirus | 2 | 2015 | 18 | 0.160 |
Why?
|
| Mammography | 1 | 2019 | 169 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 130 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2018 | 81 | 0.150 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 13 | 0.150 |
Why?
|
| Biomarkers | 1 | 2018 | 301 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2017 | 13 | 0.140 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2017 | 14 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1309 | 0.140 |
Why?
|
| Disease Progression | 1 | 2018 | 264 | 0.140 |
Why?
|
| Risk Reduction Behavior | 2 | 2014 | 108 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 748 | 0.140 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2016 | 10 | 0.140 |
Why?
|
| DNA | 1 | 2016 | 22 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 44 | 0.130 |
Why?
|
| Algorithms | 1 | 2018 | 233 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2017 | 305 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2016 | 27 | 0.130 |
Why?
|
| Hypertension | 1 | 2020 | 500 | 0.130 |
Why?
|
| Feces | 1 | 2016 | 80 | 0.130 |
Why?
|
| Gastroenteritis | 1 | 2015 | 25 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 381 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1259 | 0.120 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2015 | 228 | 0.120 |
Why?
|
| Memantine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Dopamine Agents | 1 | 2013 | 2 | 0.110 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2013 | 4 | 0.110 |
Why?
|
| Psychological Tests | 1 | 2013 | 11 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2014 | 124 | 0.110 |
Why?
|
| Taiwan | 3 | 2015 | 33 | 0.110 |
Why?
|
| Sex Factors | 3 | 2021 | 643 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2013 | 62 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 30 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 15 | 0.110 |
Why?
|
| ras Proteins | 1 | 2012 | 20 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.110 |
Why?
|
| Genome, Human | 1 | 2012 | 32 | 0.100 |
Why?
|
| Life Style | 1 | 2014 | 332 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 351 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 59 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 77 | 0.100 |
Why?
|
| Mutation | 1 | 2012 | 128 | 0.100 |
Why?
|
| Overweight | 1 | 2014 | 269 | 0.100 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2011 | 16 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2011 | 48 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2011 | 52 | 0.100 |
Why?
|
| Suntan | 1 | 2011 | 2 | 0.090 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 6 | 0.090 |
Why?
|
| Sunscreening Agents | 1 | 2011 | 5 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 13 | 0.090 |
Why?
|
| Child | 1 | 2018 | 2474 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2010 | 38 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 24 | 0.090 |
Why?
|
| Lipids | 1 | 2010 | 77 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 55 | 0.090 |
Why?
|
| Adiposity | 1 | 2010 | 66 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 119 | 0.090 |
Why?
|
| Hospitalization | 3 | 2022 | 797 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 133 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2015 | 1409 | 0.080 |
Why?
|
| Animals | 2 | 2020 | 259 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2010 | 298 | 0.080 |
Why?
|
| Information Dissemination | 2 | 2019 | 51 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1115 | 0.060 |
Why?
|
| Electroconvulsive Therapy | 1 | 2024 | 1 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2024 | 4 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 114 | 0.060 |
Why?
|
| Psychotherapy | 1 | 2024 | 58 | 0.060 |
Why?
|
| Bone Density | 1 | 2024 | 92 | 0.060 |
Why?
|
| Exudates and Transudates | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pupil Disorders | 1 | 2003 | 1 | 0.050 |
Why?
|
| Uveal Diseases | 1 | 2003 | 1 | 0.050 |
Why?
|
| Choroid Diseases | 1 | 2003 | 1 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2003 | 2 | 0.050 |
Why?
|
| Denosumab | 1 | 2023 | 1 | 0.050 |
Why?
|
| RANK Ligand | 1 | 2023 | 1 | 0.050 |
Why?
|
| Insulin | 1 | 2024 | 205 | 0.050 |
Why?
|
| Forecasting | 1 | 2023 | 75 | 0.050 |
Why?
|
| Tiotropium Bromide | 1 | 2022 | 2 | 0.050 |
Why?
|
| Muscarinic Antagonists | 1 | 2022 | 5 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2022 | 21 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2022 | 33 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2022 | 20 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2002 | 30 | 0.050 |
Why?
|
| Folic Acid | 1 | 2002 | 32 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2023 | 62 | 0.050 |
Why?
|
| China | 1 | 2002 | 130 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 1086 | 0.050 |
Why?
|
| Intermittent Positive-Pressure Breathing | 1 | 2021 | 1 | 0.050 |
Why?
|
| Airway Extubation | 1 | 2021 | 2 | 0.050 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2021 | 7 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2021 | 11 | 0.050 |
Why?
|
| Noninvasive Ventilation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2021 | 33 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 1171 | 0.050 |
Why?
|
| Comorbidity | 1 | 2023 | 594 | 0.050 |
Why?
|
| Patient Preference | 1 | 2021 | 48 | 0.050 |
Why?
|
| Dendrites | 1 | 2020 | 1 | 0.040 |
Why?
|
| Presynaptic Terminals | 1 | 2020 | 1 | 0.040 |
Why?
|
| Integrases | 1 | 2020 | 1 | 0.040 |
Why?
|
| GAP-43 Protein | 1 | 2020 | 1 | 0.040 |
Why?
|
| Odorants | 1 | 2020 | 2 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2020 | 3 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 8 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2020 | 3 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2020 | 15 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 181 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 30 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 145 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 22 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2002 | 671 | 0.040 |
Why?
|
| Decision Support Techniques | 2 | 2012 | 88 | 0.040 |
Why?
|
| Olfactory Mucosa | 1 | 2019 | 1 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2019 | 5 | 0.040 |
Why?
|
| Cell Movement | 1 | 2019 | 5 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 17 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2019 | 10 | 0.040 |
Why?
|
| Mice | 1 | 2019 | 68 | 0.040 |
Why?
|
| Publishing | 1 | 2019 | 8 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2019 | 3 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2019 | 18 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 163 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 74 | 0.040 |
Why?
|
| Protective Factors | 1 | 2015 | 32 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 102 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2570 | 0.030 |
Why?
|
| Bias | 1 | 2014 | 102 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2014 | 45 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 93 | 0.030 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2013 | 1 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2013 | 4 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Exome | 1 | 2013 | 21 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 21 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 38 | 0.030 |
Why?
|
| Peer Review | 1 | 2012 | 4 | 0.030 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2012 | 86 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2013 | 218 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 250 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 142 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 169 | 0.020 |
Why?
|
| Calcium Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2010 | 16 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 38 | 0.020 |
Why?
|
| Vitamin D | 1 | 2010 | 76 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2010 | 166 | 0.020 |
Why?
|
| Research | 1 | 2008 | 64 | 0.020 |
Why?
|